This course is no longer available

Latest User Comments

I would like to...

Course Availability

This course is only available to trainees days after purchase.
It would need to be repurchased by the trainee if not completed in the allotted time period.
This course is no longer available.
You will need to repurchase if you wish to take the course again.

Description

Immunotherapies that block CD47 stimulate macrophage phagocytosis of cancer, and they synergize with anti-CD20 passive immunotherapy in preclinical human models. CD47-blocking therapies are now under investigation in clinical trials for patients with solid and hematologic malignancies. For this presentation, I will describe our work applying these concepts to preclinical models of canine lymphoma. We validated the canine CD47/SIRPα axis as an immunotherapeutic target for canine cancer, and we have identified therapeutic agents that block canine CD47 and stimulate macrophage phagocytosis of canine lymphoma cells. We found that CD47-blocking therapies could enhance the efficacy of a speciated anti-canine CD20 antibody that is under development for canine lymphoma. The data will provide justification for testing CD47-blocking therapies in combination with anti-CD20 passive immunotherapy in companion animals. Since canine and human lymphoma bear remarkable similarity and treatment strategies, application of these strategies to the veterinary setting will inform future studies on targeting CD47 and CD20 for human disease.

Objectives

Learning Objectives:

• Understand the rationale behind cancer immunotherapy
• Appreciate the importance of evolution for species-specific and cross-species applications of biological therapies, including agents used for CD47 blockade and for CD20-directed immunotherapy
• Recognize the therapeutic principle of CD47 blockade for cancer
• Have awareness of the mechanisms of action of CD20-based immunotherapy for cancer
• Understand the mechanisms responsible for synergy of combining CD47 blockade and anti-CD20 immunotherapies for B-cell lymphoma

Dr. Jaime Modiano - Dr. Jaime Modiano completed his veterinary training and PhD in Immunology through the Veterinary Medical Scientist Training Program at the University of Pennsylvania, followed by a residency in Veterinary Clinical Pathology at Colorado State University and a post-doctoral fellowship at the National Jewish Center for Immunology and Respiratory Medicine. He served on the faculty of Texas A&M University and the University of Colorado Health Sciences Center before joining the University of Minnesota. Dr. Modiano holds the Alvin and June Perlman Endowed Chair of Animal Oncology and is the Director of the Animal Cancer Care and Research Program of the College of Veterinary Medicine and the Masonic Cancer Center at the University of Minnesota.
The research emphasis in Dr. Modiano’s laboratory is to understand how and why cancer happens and to translate basic research into clinical applications that improve the health and wellbeing of companion animals and humans.

Current Accreditations

This course has been certified by or provided by the following Certified Organization/s: